share_log

Wells Fargo Maintains Overweight on ITeos Therapeutics, Lowers Price Target to $19

Benzinga ·  Dec 19 22:58  · Ratings

Wells Fargo analyst Eva Fortea Verdejo maintains ITeos Therapeutics (NASDAQ:ITOS) with a Overweight and lowers the price target from $31 to $19.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment